Vaccinex, Inc. (VCNX): Price and Financial Metrics
VCNX Price/Volume Stats
| Current price | $1.12 | 52-week high | $12.36 |
| Prev. close | $1.26 | 52-week low | $1.08 |
| Day low | $1.08 | Volume | 455,304 |
| Day high | $1.33 | Avg. volume | 27,383 |
| 50-day MA | $3.39 | Dividend yield | N/A |
| 200-day MA | $6.16 | Market Cap | 4.93M |
VCNX Stock Price Chart Interactive Chart >
VCNX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for VCNX is -1.95 -- better than only 4.64% of US stocks.
- The ratio of debt to operating expenses for VACCINEX INC is higher than it is for about just 5.93% of US stocks.
- As for revenue growth, note that VCNX's revenue has grown 1,550% over the past 12 months; that beats the revenue growth of 99.4% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to VACCINEX INC are ZYME, MEIP, PULM, DRRX, and BYSI.
- VCNX's SEC filings can be seen here. And to visit VACCINEX INC's official web site, go to www.vaccinex.com.
VCNX Valuation Summary
- VCNX's price/sales ratio is 12.4; this is 552.63% higher than that of the median Healthcare stock.
- Over the past 62 months, VCNX's price/sales ratio has gone down 297.1.
Below are key valuation metrics over time for VCNX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VCNX | 2023-09-22 | 12.4 | -24.1 | -0.5 | -0.4 |
| VCNX | 2023-09-21 | 11.8 | -22.9 | -0.4 | -0.4 |
| VCNX | 2023-09-20 | 12.7 | -24.8 | -0.5 | -0.4 |
| VCNX | 2023-09-19 | 12.5 | -24.3 | -0.5 | -0.4 |
| VCNX | 2023-09-18 | 13.9 | -27.2 | -0.5 | -0.5 |
| VCNX | 2023-09-15 | 14.7 | -28.6 | -0.6 | -0.5 |
VCNX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VCNX has a Quality Grade of D, ranking ahead of 11.88% of graded US stocks.
- VCNX's asset turnover comes in at 0.069 -- ranking 295th of 677 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows VCNX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.069 | 0.999 | 12.119 |
| 2021-03-31 | 0.092 | 0.999 | 9.215 |
| 2020-12-31 | 0.065 | 0.997 | 8.045 |
| 2020-09-30 | 0.080 | 0.997 | 7.020 |
| 2020-06-30 | 0.069 | 0.980 | 6.213 |
| 2020-03-31 | 0.063 | 0.944 | 5.545 |
VCNX Price Target
For more insight on analysts targets of VCNX, see our VCNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $7.00 | Average Broker Recommendation | 1 (Strong Buy) |
Vaccinex, Inc. (VCNX) Company Bio
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.
Latest VCNX News From Around the Web
Below are the latest news stories about VACCINEX INC that investors may wish to consider to help them evaluate VCNX as an investment opportunity.
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatePhase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the |
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ETROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 to 10:25 am Eastern Time in New York City, NY and invites investors to participate in one |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for a dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday morning! |
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate UpdateSignificant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease (NDD) and cancer through the inhibition of SEMA4D today announced financial results for the first quarter ended March 31, 2023 and provided a corporate |
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of PepinemabTopline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it has completed enrollment goal in the SIGNAL-AD clinical trial for people with mild dementia due to Alzheimer |
VCNX Price Returns
| 1-mo | -66.80% |
| 3-mo | -79.63% |
| 6-mo | -81.31% |
| 1-year | -84.33% |
| 3-year | -95.83% |
| 5-year | -98.98% |
| YTD | -88.41% |
| 2022 | -38.03% |
| 2021 | -49.76% |
| 2020 | -57.32% |
| 2019 | 33.06% |
| 2018 | N/A |
Continue Researching VCNX
Want to do more research on Vaccinex Inc's stock and its price? Try the links below:Vaccinex Inc (VCNX) Stock Price | Nasdaq
Vaccinex Inc (VCNX) Stock Quote, History and News - Yahoo Finance
Vaccinex Inc (VCNX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...